Pfizer (NYSE:PFE) Stock Price Down 0.6% – Here’s Why

Shares of Pfizer Inc. (NYSE:PFE) traded down 0.6% during mid-day trading on Monday . The company traded as low as $25.47 and last traded at $25.50. 33,055,417 shares were traded during trading, a decline of 12% from the average session volume of 37,577,760 shares. The stock had previously closed at $25.64.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Guggenheim reaffirmed a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

The company’s 50 day moving average price is $26.26 and its 200-day moving average price is $27.46. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $146.58 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.65%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Retirement Planning Group LLC NY bought a new stake in Pfizer during the 4th quarter valued at $258,000. GF Fund Management CO. LTD. purchased a new position in shares of Pfizer during the 4th quarter valued at $3,708,000. Pinney & Scofield Inc. purchased a new position in shares of Pfizer during the 4th quarter valued at $141,000. WCG Wealth Advisors LLC grew its position in shares of Pfizer by 2.1% during the 4th quarter. WCG Wealth Advisors LLC now owns 56,107 shares of the biopharmaceutical company’s stock valued at $1,489,000 after purchasing an additional 1,151 shares in the last quarter. Finally, Pacific Point Advisors LLC purchased a new position in shares of Pfizer during the 4th quarter valued at $608,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.